PCSK9 Forum
Click here to forward this email to a colleague
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact
In the era of precision medicine, can 'OMICS' technologies guide new approaches to the management of dyslipidaemia?

Chapmab

Professor John Chapman (Pitié-Salpètriére University Hospital, and Sorbonne University, Paris, France) discusses how insights from 'OMICS' technologies into cardiometabolic phenotype could aid clinical decision making in lipid management.

Read the report »


Video round-up: Catch up with views from the experts

ProfG

Professor Gaetano De Ferrari: How can we optimise the use of PCSK9 inhibition?

Watch the video here »


DrPia

Dr Pia Kamstrup: Does lowering lipoprotein(a) matter when LDL cholesterol is very low?

Watch the video here »


Raal

Professor Derick Raal: Beyond PCSK9 monoclonal antibodies – what's in the PCSK9 pipeline?

Watch the video here »


Santos

Professor Raul Santos: Do we need to consider more than coronary complications in familial hypercholesterolaemia?

Watch the video here »


Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Our popular therapeutic guide

Read online & download second edition now »

Register now at www.pcsk9forum.org to receive the updated third edition coming soon.
New eBook
Questions & Answers

Why are new treatments needed?


Read the full answer and other questions on the PCSK9 Forum »
Educational Partners
and Supporters
Amgen The Medicines Company Sanofi
Copyright PCSK9 Forum 2018. Please click here to unsubscribe from future mailings.
‚Äč